Rosetta Genomics
MicroRNA-based Diagnostic Tests for Personalized Medicine
Company Overview
Snapshot
Founded in March 2000 by Isaac Bentwich, Rosetta Genomics operated with 51–200 employees. The company raised $6M across two funding rounds from three investors. In December 2017, Rosetta Genomics was acquired by Genoptix.
Business overview
Rosetta Genomics developed and commercialized microRNA-based and other molecular diagnostics. The company's integrated research platform combined bioinformatics and laboratory processes to discover hundreds of biologically validated novel human microRNAs. Rosetta Genomics advanced multiple diagnostic programs for cancer and various other indications, utilizing its RosettaGX platform which blended technologies like microRNA, FISH, and next-generation sequencing to enable accurate diagnosis and prognosis, thereby improving patient care management worldwide. The company operated within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Test Diagnostics & Screening, serving healthcare providers and laboratories in the United States.
Strategic signal
In June 2018, Rosetta Genomics filed for Chapter 7 bankruptcy, a significant development following its acquisition by Genoptix in December 2017. This indicates a rapid and material shift in the company's operational status and financial viability post-acquisition, signaling to investors the challenges and risks associated with integration and sustained business operations in the molecular diagnostics market.
Log in to access full profile ›Company Intelligence Q&A
- What was the most significant corporate event for Rosetta Genomics?
- In December 2017, Rosetta Genomics was acquired by Genoptix, marking a major exit for the company.
- When did Rosetta Genomics file for bankruptcy?
- Rosetta Genomics filed for Chapter 7 bankruptcy in June 2018, approximately six months after its acquisition.
- What was the total capital raised by Rosetta Genomics?
- Rosetta Genomics raised a total of $6M across two funding rounds.
- Which investors participated in Rosetta Genomics' September 2005 funding round?
- In September 2005, Rosetta Genomics raised funding with.
- What was the company's status regarding public markets?
- Rosetta Genomics was delisted from NASDAQ in June 2018, following its acquisition and subsequent bankruptcy filing.